How J.D. was paid
$1.2M in total for fiscal 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Shawn K. Singh, J.D.President, Chief Executive Officer and Director | $650,000 | — | $562,560 | — | $1,212,560 |
| Nick B. Tressler, MBAChief Financial Officer and Treasurer | $150,000 | $50,000 | $641,790 | $24,726 | $866,516 |
| Reid G. Adler, J.D.Chief Legal Officer | $450,000 | — | $187,520 | — | $637,520 |
| Elissa S. CoteChief Corporate Development and Strategy Officer | $320,682 | $35,000 | $281,925 | $58,527 | $696,134 |
| Joshua S. Prince, MBAChief Operating Officer | $415,000 | — | $187,520 | — | $602,520 |
What changed and why
- $1.2M$1,212,560 was CEO total compensation in Fiscal 2026, compared with $2,477,682 in Fiscal 2025.
- $642K$641,790 was CFO option-award compensation, the largest Fiscal 2026 option award among the NEOs.
- $50,000$50,000 and $35,000 signing bonuses were paid to the CFO and Chief Corporate Development Officer, respectively.
- 97%Over 97% of votes cast supported executive compensation at the 2025 annual meeting.
- Retention-focused equity incentives were intended to align executives with long-term stockholder value creation.
- No discretionary 401(k) contributions have been made for participating officers or employees.
Other Vistagen Therapeutics proxy statements
- 2025 proxy statement
Shawn K. Singh, J.D. paid $2.5M (+161% on the year).
Filed Jul 28, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.